THE RAT OVARIAN AUGMENTATION METHOD FOR FOLLICLE STIMULATING HORMONE

1972 ◽  
Vol 70 (4) ◽  
pp. 647-653 ◽  
Author(s):  
Peter Christiansen

ABSTRACT The specificity of the rat ovarian augmentation method (Steelman & Pohley 1953) for follicle stimulation hormone (FSH) has been studied. The addition of luteinizing hormone (LH), thyroid stimulating hormone (TSH), prolactin, ACTH and human growth hormone (GH) did not influence the ovarian response either to ovine or to human FSH. Urine extracts from 2 infants gave no positive response with a dose of one 24 hour urine sample per rat, indicating that inert material in the urine extracts does not influence the ovarian response.

1968 ◽  
Vol 59 (4) ◽  
pp. 622-628 ◽  
Author(s):  
Peter Christiansen

ABSTRACT The influence of ovine follicle stimulating hormone (NIH-FSH-S-3) on ovine luteinizing hormone (NIH-LH-S-8) in the Ventral Prostate Weight method (VPW) was studied. Adding of NIH-FSH-S-3 to NIH-LH-S-8 at ratios of 1:1, 4:1 and 10:1 gave no significantly higher responses than did NIH-LH-S-8 alone. Urinary extracts from 2 women, hypophysectomized for metastasizing mammary carcinoma and from 3 children between 2 and 5 years old (1 boy, 2 girls) gave no positive response with the doses employed (1/4 of a 24 hours urine sample total per rat). It is concluded that the Ventral Prostate Weight method in hypophysectomized rats is specific for the assay of luteinizing hormone.


1990 ◽  
Vol 73 (5) ◽  
pp. 731-735 ◽  
Author(s):  
Lee B. Jacoby ◽  
E. Tessa Hedley-Whyte ◽  
Karen Pulaski ◽  
Bernd R. Seizinger ◽  
Robert L. Martuza

✓ Benign pituitary adenomas are among the most common neurosurgical tumors and account for a diversity of clinical syndromes due to their hormone content and release. To determine whether these tumors arise from a single cell or multiple cells, the authors studied X chromosome inactivation in deoxyribonucleic acid (DNA) isolated from pituitary adenomas in women. Tumors of three different hormonal subtypes were examined. One tumor contained cells immunoreactive for prolactin and human growth hormone; one tumor contained foci immunoreactive for the β-subunits of luteinizing hormone and follicle-stimulating hormone; and the third tumor had no immunoreactive prolactin, human growth hormone, β-subunits of thyroid-stimulating hormone, luteinizing hormone, or follicle-stimulating hormone, or the α-subunit. Analysis of the DNA revealed that, in each of the three pituitary tumors, one X chromosome was active in all cells and one X chromosome was inactive, indicating that each of these tumors was monoclonal in origin. It is concluded that clinically evident pituitary tumors arise from a genetic mutation in a single cell.


2010 ◽  
Vol 67 (1) ◽  
pp. 42-47
Author(s):  
Danijela Radojkovic ◽  
Slobodan Antic ◽  
Milica Pesic ◽  
Milan Radojkovic ◽  
Dijana Basic ◽  
...  

Background/Aim. Nipple discharge syndrome is a clinical entity capable of presenting various disorders such is mammary infection (nonpuerperal and puerperal mastitis), intraductal papillomas, fibrodenoma, breast cancer and hyperprolactinemia syndrome. The aim of the study was to determine differencies in cytological features of mammary secretion in patients with hyperprolactinemia and those with normal serum prolactin levels and to define the role of growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone in creating cellular profile of breast secretion. Methods. The study included 50 patients with nipple discharge syndrome. The patients were devided into the clinical group (27 patients with hyperprolactinemia and nipple discharge) and the control group I (23 patients with normal serum prolactin and nipple discharge). The control group II included the patients of the clinical group achiving normalised serum prolactin levels after the treatment of hyperprolactinemia. Serum prolactin, follicle-stimulating hormone and luteinizing hormone levels were assessed by RIA using commercial kits IRMA hPRL, hLH and hFSH, (INEP, Zemun, Serbia) while serum growth hormone and thyroid-stimulating hormone levels were assessed by RIA using commercial kits LKB-wallac. Cytologic evaluation of samples, taken from all the patients with mammary secretion, was done using standard techniques of staining Haemathoxilin-eozine and May- Gr?nwald/Giemsa. Results. Our results showed a significantly higher presence of lipid and protein material in clinical group, in comparison with the control group I (p < 0.01). Also, our data demonstrated significantly higher number of ductal epithelial cells (p < 0.05) and ductal histiocities (p < 0.001) in the clinical group, compared with the control group I. Macrophagies frequency was proportionally higher in clinical group (44.44%) compared the control group I (17.39%). Erythrocites were significantly lower in the clinical group (p < 0.001) than in the control group I. Significantly decreased mammary secretion (p < 0.01), lower lipid (p < 0.01) and protein synthesis (p < 0.01), and less presence of all cellular categories (p < 0.01) were obtained after normalization of serum prolactin levels. Conclusion. Growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone did not show significant influence on creating cytological features of mammary secretion. The most expressive role, hyperprolactinemia demonstrated in the domain of mammary ductal secretory activity, making mammary secretion reach in lipid and protein material and simultaneously increasing number of ductal epithelial cells, ductal histiocytes and 'foam cells'- macrophages. These cytological findings indicate that hyperprolactinemia promote periductal and intraductal steril inflammation which withdraws after serum prolactin normalization.


1981 ◽  
Vol 34 (3) ◽  
pp. 321 ◽  
Author(s):  
GA Smythe ◽  
JF Brandstater ◽  
RF Vining

The induction of hyperprolactinaemia in the male rat following chronic high-dose oestrogen administration over 3 months was associated With a significant inhibition of the secretion of growth hormone (OH) (P < 0�02) thyroid stimulating hormone (TSH) (P < 0�0025), luteinizing hormone (LH) and follicle stimulating hormone (FSH) (both P < 0�01). Acute, but not chronic, administration of bromocriptine (1 mg/kg) to these hyperprolactinaemic animals had the effect of normalizing the serum levels of GH and TSH but not those of LH or FSH. While the effects observed on GH, TSH, LH and FSH following induction of hyperprolactinaemia are likely to be consequential to brain actions of prolactin, the present data do not exclude the possibility of direct actions of oestrogen itself.


Sign in / Sign up

Export Citation Format

Share Document